Atorvastatin Loading Dose in STEMI Before Primary PCI: Evidence on Epicardial Flow, No-Reflow Phenomenon, and Clinical Outcomes

Abstract

Background: Primary percutaneous coronary intervention remains the preferred reperfusion strategy for patients with ST-segment elevation myocardial infarction when it can be performed rapidly, because restoration of infarct-related artery patency is central to myocardial salvage and survival. However, successful opening of the epicardial artery does not always translate into adequate myocardial tissue reperfusion. Impaired final Thrombolysis in Myocardial Infarction flow, slow-flow, no-reflow, reduced myocardial blush grade, and incomplete ST-segment resolution are important markers of larger infarct size, adverse ventricular remodeling, heart failure, and mortality. Therefore, adjunctive pharmacological strategies that improve both epicardial and microvascular reperfusion are clinically relevant in contemporary STEMI care.

High-dose atorvastatin loading before PCI has attracted interest because statins exert rapid pleiotropic effects beyond lipid lowering, including improvement of endothelial function, attenuation of inflammation, reduction of oxidative stress, inhibition of platelet activation, stabilization of vulnerable plaque, and modulation of thrombus burden. These mechanisms are highly relevant in STEMI, where plaque rupture, intense thrombosis, distal embolization, vasoconstriction, and microvascular obstruction contribute to impaired TIMI flow and no-reflow. Early randomized trials in PCI populations suggested that atorvastatin pretreatment reduces periprocedural myocardial injury, while STEMI-focused studies have examined its impact on final TIMI flow, corrected TIMI frame count, myocardial blush, ST-segment resolution, and short-term clinical outcomes.

The available evidence suggests that atorvastatin loading before primary PCI is biologically plausible, safe, inexpensive, and potentially beneficial, particularly in patients actually undergoing PCI. The largest ACS trial, SECURE-PCI, did not show a significant reduction in 30-day major adverse cardiovascular events in the overall ACS population, but suggested benefit among patients treated with PCI and in STEMI subgroups. Smaller STEMI trials and meta-analyses have reported improvement in angiographic and electrocardiographic reperfusion indices, including better final TIMI flow and lower no-reflow rates. Accordingly, early high-intensity statin therapy should be viewed as an important component of STEMI management, while the specific incremental effect of pre-PCI atorvastatin loading on TIMI flow remains an area requiring careful interpretation and further study.